Expanded Access Program for Participants who Completed Study 13-601 and Continue to Clinically Benefit from Cerdulatinib

Study identifier:20-605

ClinicalTrials.gov identifier:NCT04757259

EudraCT identifier:N/A

CTIS identifier:N/A

Other

Official Title

An Expanded Access Protocol for Patients Who Completed Study 13-601 and Continue to Clinically Benefit from Cerdulatinib

Medical condition

Relapsed/refractory chronic lymphocytic leukemia, Non-hodgkin's Lymphoma

Phase

-

Healthy volunteers

-

Study drug

cerdulatinib

Sex

All

Actual Enrollment

-

Study type

Expanded Access

Age

18 Years +

Date

Study Start Date: -
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Mar 2024 by Alexion Pharmaceuticals

Sponsors

Alexion Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria